Saturday 17 October 2026
Export PLX’s income statement to Excel — free account
Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024. In the quarter to June 2026, revenue grew 27.1%, EPS grew 2,281.0% and free cash flow fell 94.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.62
0.08
−2.96%
Follow PLX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
30.79 | 0.00 | 11.30 | 9.71 |
P/S ratio |
2.85 | 2.68 | 2.27 | 2.31 | |
P/FCF ratio |
0.00 | 0.00 | 13.33 | 24.30 | |
P/Operating CF |
(47.16) | 69.65 | 7.87 | (17.92) | |
P/B ratio |
3.33 | 2.93 | 2.58 | 2.61 | |
Price to Tangible BV |
3.33 | 2.93 | 2.58 | 2.61 | |
EV/Sales |
2.70 | 2.48 | 1.85 | 2.05 | |
EV/EBITDA |
21.44 | 0.00 | 6.64 | 6.64 | |
EV/Operating CF |
(16.62) | (10.88) | 9.38 | 16.64 | |
EV/FCF |
(14.26) | (9.58) | 10.90 | 21.53 | |
Quick Ratio |
2.00 | 1.50 | 2.00 | 1.84 | |
Current Ratio |
3.03 | 2.51 | 3.15 | 2.94 | |
Net Debt/EBITDA |
(11.73) | 7.25 | (2.40) | (8.15) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.86 | 0.68 | 0.87 | 0.85 | |
Operating CF/Net income |
(1.58) | (0.37) | 1.20 | (2.75) | |
Capex/Depreciation |
(1.34) | (1.04) | (1.88) | (1.46) | |
Research and Development Expense of Revenue |
25.02% | 61.77% | 16.08% | 21.87% | |
Selling, General and Administrative Expense of Revenue |
16.41% | 38.65% | 9.04% | 15.64% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.35% | 8.02% | 1.58% | 2.00% | |
Graham Net Nets |
0.21 | 0.23 | 0.30 | 0.29 | |
Graham Number |
1.04 | 0.00 | 1.91 | 2.20 | |
Earnings Yield |
3.25% | (4.88%) | 8.85% | 10.30% | |
Free Cash Flow Yield |
(6.64%) | (9.64%) | 7.50% | 4.11% | |
Revenue per Share |
0.23 | 0.12 | 0.42 | 0.25 | |
Operating CF per Share |
(0.05) | 0.03 | 0.28 | (0.13) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.05) | 0.02 | 0.27 | (0.14) | |
Cash per Share |
0.37 | 0.39 | 0.65 | 0.52 | |
Shareholders Equity per Share |
0.67 | 0.61 | 0.84 | 0.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.67 | 0.61 | 0.84 | 0.89 | |
Free Cash Flow |
(4.23) | 1.63 | 21.26 | (10.99) | |
Working Capital |
44.56 | 40.16 | 58.97 | 60.83 | |
Capital Expenditures |
(0.50) | (0.40) | (0.76) | (0.59) | |
Net Current Asset Value |
37.15 | 32.56 | 51.25 | 53.29 | |
EV/EBIT |
26.19 | 0.00 | 7.16 | 7.09 | |
Capex to Sales |
0.03 | 0.04 | 0.02 | 0.03 | |
Price to Operating Income |
27.64 | 0.00 | 8.76 | 8.00 | |
| Other line items | |||||
Average Receivables |
8.31 | 5.87 | 4.60 | 12.97 | |
Average Payables |
21.63 | 24.63 | 24.43 | 26.17 | |
Average Inventory |
19.23 | 23.49 | 24.99 | 26.71 | |
Average Assets |
71.91 | 77.88 | 88.11 | 94.41 | |
Average Common Equity |
42.67 | 45.72 | 56.22 | 60.65 |
Columns are period end dates